Market Access News | pharmaphorum

News

BMS chases MSD/Seagen with first-line bladder cancer filing

The FDA has started a priority review of Bristol-Myers Squibb Opdivo in combination with cisplatin as a first-line therapy for advanced urothelial carcinoma (UC), setting

News

Pharma accuses UK of ‘mixed messages’ on rebate schemes

The pharma industry and the UK government may have reached an accord on the voluntary scheme of rebates used to limit rises in medicines spending in the UK, but the altern

News

FDA starts review of Padcev/Keytruda for bladder cancer

The FDA has kicked off a priority review of a new combination regimen for previously untreated, locally advanced or metastatic urothelial carcinoma (UC), the most common f

News

FDA elevates chief scientist Bumpus to the number two role

FDA chief scientist Namandjé Bumpus has been named as principal deputy commissioner, replacing long-serving Janet Woodcock when she steps down early next year.

News

Astellas builds case for menopause drug fezolinetant

New data for Astellas Pharma’s non-hormonal menopause therapy fezolinetant has shown it remains effective to 24 weeks, consolidating the evidence of the drug as it starts

News

FDA kicks off review of Karuna’s schizophrenia drug KarXT

Karuna Therapeutics said this morning that the FDA has formally started its review of KarXT, aiming to become the first drug to reach the market for schizophrenia with a n

BMS chases MSD/Seagen with first-line bladder cancer filing

Pharma accuses UK of ‘mixed messages’ on rebate schemes

FDA starts review of Padcev/Keytruda for bladder cancer

FDA elevates chief scientist Bumpus to the number two role

Astellas builds case for menopause drug fezolinetant

FDA kicks off review of Karuna’s schizophrenia drug KarXT

Ipsen' Bylvay fluffs its lines in biliary atresia trial

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks